| dc.contributor.author | Acheampong, Desmond O. | |
| dc.contributor.author | Adokoh, Christian K. | |
| dc.contributor.author | Ampomah, Paulina | |
| dc.contributor.author | Agyirifo, Daniel S. | |
| dc.contributor.author | Dadzie, Isaac | |
| dc.contributor.author | Ackah, Francis A. | |
| dc.contributor.author | Asiamah, Ernest A. | |
| dc.date.accessioned | 2023-10-17T16:30:06Z | |
| dc.date.available | 2023-10-17T16:30:06Z | |
| dc.date.issued | 2017 | |
| dc.identifier.uri | http://hdl.handle.net/123456789/9583 | |
| dc.description.abstract | Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and ra- diotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate per- petual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibod- ies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique char- acteristics. This review discusses up to date therapeutic potentials of BsAbs. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Protein & Peptide Letters | en_US |
| dc.subject | Antibody, | en_US |
| dc.subject | bispecific antibody (BsAb), | en_US |
| dc.subject | immunotherapeutic agent, | en_US |
| dc.subject | cancer therapy, | en_US |
| dc.subject | diabody, | en_US |
| dc.subject | antitumor. | en_US |
| dc.title | Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy | en_US |
| dc.type | Article | en_US |